Venaxis (NASDAQ:APPY) is a very interesting diagnostic substances company. The diagnostics are not necessarily the most glamorous part of the industry, and yet Venaxis has put itself in a position where it could provide significant return on investment for long-term oriented shareholders. Currently, the company has only one product in development, APPY 1. As APPY 1 advances through the clinical process, and as Venaxis switches its focus from product development to product commercialization, shareholders have the potential to benefit from significant long-term upside in Venaxis shares.
APPY 1 is Venaxis's diagnostic substance for the diagnosis of appendicitis. Currently, testing for appendicitis requires a multitude of tests in a hospital setting, which increase costs associated with the...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|